Drug intelligence / Profile preview

CAR-T-19F

Development stage: Preclinical
Lead developer: Pharos Vaccine
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CAR-T-19F is a preclinical-stage chimeric antigen receptor T-cell (CAR-T) therapy being developed by Pharos Biologicals. It is designed to treat B-cell malignancies, specifically B-cell Acute Lymphoblastic Leukemia (ALL) and Diffuse Large B-cell Lymphoma (DLBCL). The therapeutic mechanism involves the genetic modification of T cells to express a receptor that targets the CD19 antigen, a well-established biomarker for B-cell lineage cancers. By binding to CD19 on the surface of malignant cells, CAR-T-19F cells initiate a cytotoxic immune response to eliminate the tumor.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on CAR-T-19F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR-T-19F.

Explore the full profile